Close Menu

NEW YORK (GenomeWeb) – Veracyte announced after the close of the market on Monday that its fourth quarter revenues grew 32 percent year over year and beat the consensus Wall Street estimate.

For the three months ended Dec. 31, 2018, the South San Francisco, California-based genomics diagnostics firm posed $25.8 million in revenues, up from $19.6 million in Q4 2017 and above analysts' average estimate of $24.4 million.

Total genomic test volume was up 28 percent year over year to 9,154 tests in the quarter, Veracyte said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.